RXC004 (PORCUPINE2)

February 2023 AMMF understands that the Phase 2 RXC004 (PORCUPINE2) study has now closed to recruitment.  

April 2024: We understand that the revised Phase 3 study for those with biliary tract cancer – cholangiocarcinoma, gallbladder or ampullary cancer – using RXC004 + pembrolizumab, ie, RXC004 with the addition of an immunotherapy, is now open in some centres and that there will be no patient pre-selection required in terms of molecular profile.

If you are interested in this study, please speak to your consultant about this.  

We will further update the information on the Phase 2 and Phase 3 studies as soon as we can. 

A Phase 2 Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy

This second line study is open for molecularly unselected patients with advanced biliary tract cancer, ie,  cholangiocarcinoma, gallbladder or ampullary cancer, who have developed disease progression after first-line chemotherapy only.

Patients need to start treatment within 6 weeks of the CT scan showing disease progression in order to avoid patients becoming too unwell to benefit. RXC004 is a tablet treatment targeting the WNT pathway, which is over-active in biliary tract cancer.

It is also open to those with pancreatic cancer who have a specific mutation, RNF43, in their tumour.

This trial is current open and recruiting in the UK at the following sites:

More sites are expected to open soon.

For further information, including new sites, see:
https://clinicaltrials.gov/ct2/show/study/NCT04907851